Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. [electronic resource]
Producer: 20201207Description: 516-522 p. digitalISSN:- 1600-0641
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carcinoma, Hepatocellular -- drug therapy
- Diarrhea -- chemically induced
- Female
- Follow-Up Studies
- Humans
- Kaplan-Meier Estimate
- Liver Neoplasms -- drug therapy
- Male
- Middle Aged
- Pravastatin -- adverse effects
- Prognosis
- Progression-Free Survival
- Quality of Life
- Sorafenib -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.